Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE: 688336)
Health Care · Biotechnology · CN
CN¥38.10
-8.04% today · +5.3% 1Y
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE: 688336) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.10B and employs 1,023 people.
Over the last twelve months the share price has gained 5.3%, trading between 34.34 and 66.62.
Tweenvest scores Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd across four factors: quality 72/100, value 53/100, growth 80/100, dividend 45/100. Its strongest factor is growth.
688336 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.10B
- Revenue (TTM)
- $651.10M
- P/E
- 11.11
- EPS
- 3.43
- Dividend yield
- 0.87%
- Beta (5Y)
- 0.33
- 52-week high
- CN¥66.62
- 52-week low
- CN¥34.34
- Avg volume (3M)
- —
- Shares outstanding
- 896.23M
- Employees
- 1,023
- Next earnings
- —
About Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
- ISIN
- CNE1000062X2
- Founded
- 2002
- Listed since
- Jul 22, 2020
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PTC Therapeutics, Inc.NasdaqGS: PTCT | $5.40B | $63.65 | -1.62% |
| Cogent Biosciences, Inc.NasdaqGS: COGT | $5.38B | $30.38 | -2.00% |
| CRISPR Therapeutics AGNasdaqGM: CRSP | $5.16B | $51.83 | -2.92% |
| Scholar Rock Holding CorporationNasdaqGS: SRRK | $5.14B | $42.14 | -0.12% |
| Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.SHSE: 603392 | $5.09B | CN¥26.96 | -1.39% |
| Shanghai RAAS Blood Products Co., Ltd.SZSE: 002252 | $4.98B | CN¥5.06 | -4.89% |
| Travere Therapeutics, Inc.NasdaqGM: TVTX | $4.91B | $52.52 | +0.76% |
| Chongqing Zhifei Biological Products Co., Ltd.SZSE: 300122 | $4.90B | CN¥13.70 | -2.00% |
Figures last refreshed Oct 11, 2026.